VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation – Agreeing the Phase 2 Trial to Be Served as One of the Two Pivotal Studies.

HONG KONG and WENZHOU, China, June 9, 2025 /PRNewswire/ — VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced today that it received written preliminary comments for the Type C meeting to be…